Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPB1 | P04792 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MERTK | Q12866 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | MYOC | Q99972 | 1/20 | 0.51 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.50 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.50 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.50 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.50 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL57257 | 0.88 | VCAM1 (0.61) | MEN1KMT2AMAPTNPC1PKM | |
| SCHEMBL16089350 | 0.88 | VCAM1 (0.61) | MEN1KMT2AMAPTNPC1PKM | |
| Selenium SCHEMBL9497333 | 0.86 | VCAM1 (0.59) | MEN1KMT2AMAPTNPC1PKM | |
| 4,4'-Oxybis(Nitrobenzene) SCHEMBL134332 | 0.84 | HSPB1 (0.79) | HSPB1MEN1KMT2AMAPTNPC1 | |
| SCHEMBL9183872 | 0.84 | HSPB1 (0.79) | HSPB1MEN1KMT2AMAPTNPC1 | |
| SCHEMBL2011179 | 0.84 | HSPB1 (0.79) | HSPB1MEN1KMT2AMAPTNPC1 | |
| SCHEMBL11689190 | 0.84 | HSPB1 (0.79) | HSPB1MEN1KMT2AMAPTNPC1 | |
| SCHEMBL7429410 | 0.84 | ALDH1A1 (0.61) | HSPB1MEN1KMT2AMERTKMAPT | |
| SCHEMBL2961542 | 0.82 | KCNJ1 (0.55) | MEN1KMT2AMAPTNPC1PKM | |
| SCHEMBL27214761 | 0.82 | KCNJ1 (0.55) | MEN1KMT2AMAPTNPC1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011078370-A1 | NOVEL PARABANIC ACID DERIVATIVE AND DRUG HAVING THE SAME AS ACTIVE INGREDIENT | 杏林製薬株式会社 (JP) | 2011-06-30 | — | — | WO | disclosed |
| EP-1265866-B1 | ARYL SUBSTITUTED PYRIDINES, PYRIMIDINES, PYRAZINES AND TRIAZINES AND THE USE THEREOF | EURO CELTIQUE SA (LU) | 2010-07-21 | — | — | EP | disclosed |
| EP-1265866-B1 | ARYL SUBSTITUTED PYRIDINES, PYRIMIDINES, PYRAZINES AND TRIAZINES AND THE USE THEREOF | EURO CELTIQUE SA (LU) | 2010-07-21 | — | — | EP | disclosed |
| US-20070185176-A1 | Heparanase inhibitors and uses thereof | INSIGHT BIOHARMACEUTICALS LTD. (IL) | 2007-08-09 | — | — | US | disclosed |
| EP-1720828-A2 | HEPARANASE INHIBITORS AND USES THEREOF | Insight Biopharmaceuticals Ltd (IL) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005074375-A2 | HEPARANASE INHIBITORS AND USES THEREOF | INSIGHT BIOPHARMACEUTICALS LTD (IL) | 2005-08-18 | — | — | WO | disclosed |
| US-6867210-B2 | Aryl substituted pyrimidines | EURO-CELTIQUE S.A. (LU) | 2005-03-15 | — | — | US | disclosed |
| US-20050043305-A1 | Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof | EURO-CELTIQUE S.A. (LU) | 2005-02-24 | — | — | US | disclosed |
| US-20040192691-A1 | Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof | EURO-CELTIQUE S.A. | 2004-09-30 | — | — | US | disclosed |
| CN-1422254-A | Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof | EURO CELTIQUE SA (LU) | 2003-06-04 | — | — | CN | disclosed |
| EP-1265866-A2 | ARYL SUBSTITUTED PYRIDINES, PYRIMIDINES, PYRAZINES AND TRIAZINES AND THE USE THEREOF | Euro-Celtique S.A. (LU) | 2002-12-18 | — | — | EP | disclosed |
| US-20020040025-A1 | Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof | PURDUE PHARMA L.P. | 2002-04-04 | — | — | US | disclosed |
| WO-2001068612-A2 | ARYL SUBSTITUTED PYRIDINES, PYRIMIDINES, PYRAZINES AND TRIAZINES AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2001-09-20 | — | — | WO | disclosed |
| US-4596680-A | Heating in the presence of basic catalyst two aryl carbonates | INSTITUT FRANCAIS DU PETROLE (FR) | 1986-06-24 | — | — | US | disclosed |
| EP-0091851-B1 | PROCESS FOR PREPARING ARYL ETHERS CARRYING DIFFERENT SUBSTITUENTS ON THE TWO AROMATIC NUCLEI | Institut Français du Pétrole (FR) | 1986-02-19 | — | — | EP | disclosed |
| EP-0091851-A1 | Process for preparing aryl ethers carrying different substituents on the two aromatic nuclei | Institut Français du Pétrole (FR) | 1983-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185176-A1 | Heparanase inhibitors and uses thereof | HPSE, ENGASE, HEXA | HSPB1 765/4885MEN1 2391/4885KMT2A 2842/4885 |
| US-20050043305-A1 | Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof | CACNA1S, CACNA1C, KYNU | HSPB1 2292/4885MEN1 4858/4885KMT2A 3260/4885 |
| US-20040192691-A1 | Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof | CACNA1S, KYNU, CACNA1C | HSPB1 1783/4885MEN1 4858/4885KMT2A 3625/4885 |
| US-20020040025-A1 | Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof | CACNA1S, KYNU, CACNA1C | HSPB1 1783/4885MEN1 4858/4885KMT2A 3625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.